Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCN Cyclerion Therapeutics	$3.05	$3.10	$1.75 ▼ $6.75	$8.27M	1.84	3,929 shs	132 shs
EPIX ESSA Pharma	$6.40	$8.47	$2.56 ▼ $11.67	$283.14M	1.62	58,040 shs	130,486 shs
MRKR Marker Therapeutics	$4.43 +5.5%	$4.27	$0.76 ▼ $9.68	$37.30M	1.5	20,954 shs	11,907 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCN Cyclerion Therapeutics	-6.73%	-12.06%	-9.18%	-19.71%	-52.18%
EPIX ESSA Pharma	0.00%	-13.86%	-29.13%	-27.19%	+136.16%
MRKR Marker Therapeutics	+5.73%	+0.68%	-9.78%	+6.22%	+381.52%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	1.9902 of 5 stars	3.5	4.0	0.0	0.0	0.0	3.3	0.0
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	3.00	Buy	$16.50	157.81% Upside
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCN Cyclerion Therapeutics	$1.62M	5.10	N/A	N/A	$4.62 per share	0.66
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
MRKR Marker Therapeutics	$3.31M	11.90	N/A	N/A	$1.58 per share	2.80
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCN Cyclerion Therapeutics	-$5.26M	-$5.51	N/A	∞	N/A	N/A	-111.79%	-74.10%	5/9/2024 (Estimated)
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
MRKR Marker Therapeutics	-$8.24M	N/A	0.00	∞	N/A	-142.62%	-39.89%	-25.45%	5/21/2024 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A

Latest REPH, MRKR, EPIX, and CYCN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCN Cyclerion Therapeutics	N/A	3.85	3.85
EPIX ESSA Pharma	N/A	40.74	40.74
MRKR Marker Therapeutics	N/A	5.57	5.57
REPH Recro Pharma	2.27	3.24	2.74

Ownership

Institutional Ownership

Company	Institutional Ownership
CYCN Cyclerion Therapeutics	75.62%
EPIX ESSA Pharma	75.12%
MRKR Marker Therapeutics	22.39%
REPH Recro Pharma	62.34%

Insider Ownership

Company	Insider Ownership
CYCN Cyclerion Therapeutics	13.10%
EPIX ESSA Pharma	14.70%
MRKR Marker Therapeutics	24.10%
REPH Recro Pharma	14.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCN Cyclerion Therapeutics	1	2.71 million	2.36 million	No Data
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
MRKR Marker Therapeutics	8	8.90 million	6.76 million	Not Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable

REPH, MRKR, EPIX, and CYCN Headlines

Source	Headline
	Dorf Ketal's Indian unit acquires veterinary pharma brand vccircle.com - April 10 at 10:57 PM
	Fuji Pharma Co. Ltd. wsj.com - January 30 at 3:34 PM
	Aurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 crore moneycontrol.com - November 22 at 10:47 PM
	Retaining the human element of AI within pharma and healthcare pharmaphorum.com - November 21 at 10:06 AM
	Here's what Wall Street expects from Recro Pharma's earnings report markets.businessinsider.com - November 7 at 12:00 PM
	US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits theguardian.com - August 16 at 1:59 AM
	Mankind Pharma share price livemint.com - August 9 at 12:30 PM
	What Wall Street expects from Recro Pharma's earnings markets.businessinsider.com - August 9 at 7:25 AM
	Mankind Pharma Ltd (MNKI) investing.com - August 3 at 9:00 AM
	Eversana and Amazon plan generative AI push in pharma pharmaphorum.com - July 30 at 11:21 PM
	Aurobindo Pharma Ltd. ndtv.com - July 25 at 12:39 AM
	Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps bizjournals.com - June 30 at 12:44 PM
	Pharma reform: Patients can’t afford to wait. Act now. politico.eu - June 13 at 3:41 PM
	Sun Pharma reports "information security incident"; isolates impacted IT assets health.economictimes.indiatimes.com - March 9 at 7:26 AM
	Watch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNL ijr.com - March 2 at 12:30 AM
	Aurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividend moneycontrol.com - February 17 at 8:43 PM
	Paytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focus financialexpress.com - December 20 at 8:48 AM
	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL benzinga.com - June 24 at 9:08 AM
	Societal CDMO Inc reuters.com - April 20 at 9:24 AM
	Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation finanznachrichten.de - March 22 at 10:51 PM
	Recro Pharma Rebrands to Societal CDMO Inc. contractpharma.com - March 22 at 5:51 PM
	Is Recro Pharma (REPH) a Worthy Investment? finance.yahoo.com - March 22 at 8:32 AM
	Recap: Recro Pharma Q4 Earnings benzinga.com - March 1 at 11:55 PM
	Recro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilities contractpharma.com - February 23 at 9:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cyclerion Therapeutics

NASDAQ:CYCN

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Marker Therapeutics

NASDAQ:MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial